Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
View directory record Official record
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

NCT05008549
View directory record Official record
Conditions
Attention, Mood
Interventions
Cranberry Juice Product
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 29, 2026, 4:20 PM EDT
Active, not recruiting Phase 2 Interventional

Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study

NCT03667404
View directory record Official record
Conditions
Parkinson Disease, Intestinal Bacteria Flora Disturbance, Dietary Modification
Interventions
Resistant maltodextrin, maltodextrin
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

NCT02969408
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 29, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome

NCT07432490
View directory record Official record
Conditions
Glut1 Deficiency, GLUT1DS1
Interventions
L-fucose, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945
View directory record Official record
Conditions
Migraine
Interventions
zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

NCT03312777
View directory record Official record
Conditions
Pain
Interventions
Omnitram, Tramadol, Placebo
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

NCT05157763
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Interventions
EscharEx 5% (EX-02 formulation)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aventura, Florida • Brandon, Florida • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

NCT02189304
View directory record Official record
Conditions
COPD
Interventions
PT010, PT009, Symbicort Turbohaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
View directory record Official record
Conditions
Keloid
Interventions
STP705, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 29, 2026, 4:20 PM EDT
Not listed Not applicable Interventional

Safety Study of Post Tonsillectomy Ibuprofen Use in Adults

NCT01837810
View directory record Official record
Conditions
Secondary Post Tonsillectomy Hemorrhage, Primary Post Tonsillectomy Hemorrhage
Interventions
Ibuprofen
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Fort Sam Houston, Texas • Lackland Air Force Base, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

NCT01647659
View directory record Official record
Conditions
Cancer
Interventions
Trametinib tablet, Trametinib pediatric formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

NCT01725685
View directory record Official record
Conditions
Asthma
Interventions
FF 400 mcg, UMEC 500 mcg, FF/UMEC 400/500 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cardiac Safety of Indacaterol

NCT01263808
View directory record Official record
Conditions
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

NCT04676633
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 29, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT01440517
View directory record Official record
Conditions
Diabetes Mellitus, Heart Failure
Interventions
Tc99m-Maraciclatide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

NCT01314599
View directory record Official record
Conditions
Acute Leukemia
Interventions
PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 29, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 29, 2026, 4:20 PM EDT
Active, not recruiting Phase 2 Interventional

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Active, not recruiting Phase 2 Interventional

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

NCT04406649
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
44
States / cities
Encino, California • Long Beach, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 29, 2026, 4:20 PM EDT